Aryeh Jason 4

What Happened
Aryeh Jason, a director of Lifecore Biomedical, Inc. (LFCR), was granted 25,907 restricted stock units (RSUs) on June 4, 2026 (reported on Form 4 filed 2026-06-05). The award is coded as an acquisition/award (A); no cash price is reported and no immediate market value or proceeds are provided. Per the filing, each RSU converts into one share of Lifecore common stock on a 1:1 basis when settled.

Key Details

• Transaction date: June 4, 2026; Form 4 filed: June 5, 2026 (filed the next business day).
• Transaction type/code: Grant/Award (A) of 25,907 RSUs; price listed as N/A (typical for RSU grants).
• Vesting: RSUs vest on the earlier of June 4, 2027 or the Company’s 2027 annual meeting of stockholders, provided that meeting is at least 50 weeks after June 4, 2026 (per footnote).
• Conversion: RSUs convert into common stock on a 1-for-1 basis (per footnote).
• Shares owned after transaction: Not reported in the provided excerpt — check the full Form 4 for total beneficial ownership.
• Timeliness: Filing appears timely (Form 4 generally due within two business days for insiders).

Context
RSU grants are a form of equity compensation and do not represent an immediate purchase or sale of stock; shares are only issued when the units vest and are settled. Such awards are common for directors and executives and are generally intended as compensation/retention rather than a direct signal of buying or selling intent.